Double-blind studies have been the gold standard in drug and vaccine development for decades. But should they be? Is the current regulatory regime saving or costing lives? Is there a way in which free market competition might improve upon the FDA’s tight-fisted control of the pharmaceutical development process? Join us for this timely conversation with law professor Richard Epstein on drug and vaccine development, the limits of bureaucratic regulation, and the capacity of markets to share knowledge, control risk, and spur life-saving innovation.